# Monte Carlo Simulations of Suprathermal Enhancement in Advanced Nuclear Fusion Fuels

Preprint · Marcus Borscz, Thomas A. Mehlhorn, Patrick A. Burr, Igor Morozov, Sergey Pikuz

- Archive id: arxiv:2604.06769
- Published: 2026-04-08
- arXiv: https://arxiv.org/abs/2604.06769
- Source URL: https://arxiv.org/abs/2604.06769
- PDF: https://arxiv.org/pdf/2604.06769
- Provenance: arxiv

## Abstract

Suprathermal fusion reactions, initiated by energetic particles slowing down and scattering in dense plasmas, can modify the burn dynamics at inertial confinement fusion (ICF) regimes. A 0D time-dependent Monte-Carlo code has been developed to assess the suprathermal energy gain from fast fusions in DT, deuterium, $^{11}$BH$\_3$ and $^{11}$BHDT fuels. It incorporates modified Li-Petrasso stopping powers, thermal broadening of cross-sections, anisotropic nuclear elastic and neutron elastic scattering, and a physical model for the p$^{11}$B alpha-particle spectra. Results show that earlier predictions of suprathermal criticality in pure deuterium are overestimated by more than an order of magnitude; no realistic density-temperature regime supports a self-sustaining chain reaction. Only DT demonstrates a critical regime provided there is no neutron leakage. Fast protons in $^{11}$BH$\_3$ have an optimum energy of 4 MeV for maximising suprathermal enhancement. In this case the additional energy from fast fusions is unlikely to exceed 40% of the initial proton beam energy. The possibility of an alpha-particle-driven "avalanche" mechanism is ruled out since the ionic stopping is dominated by collisions involving small energy transfer. Suprathermal multiplication processes are dominated by neutron-driven ion up-scattering and likely play a limited role in purely aneutronic fuels.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.